Attrition in longitudinal randomized controlled trials: home visits make a difference

Table 4 Trial outcomes in Routine F/U and Home F/U patients

CARDIAC AND NEUROLOGIC MORBIDITY AND MORTALITY (N=248)		P	# OF COMPLICATIONS
Low MAP (n=124)	12.9%		Perioperative	13
			6 months	4
			Total	17
		0.026
High MAP (n=124)	4.8%		Perioperative	4
			6 months	4
			Total	6
Total Cardiac and neurologic morbidity and mortality	8.9%		Total	22
Neurocognitive Dysfunction at 6 months (n=225)
Low MAP	12.4%	0.86	6 months	14
High MAP	11.6%		6 months	13
Total	12.0%			27
Functional Decline at 6 months (n=217)
Low MAP	8.3%	0.62	6 months	9
High MAP	6.5%		6 months	7
Total	7.4%			16
Combined Trial Outcome (n=248)
Low MAP	27.4%	0.032		34
High MAP	16.1%			20
Total	21.8%			54

(Surveillance on 248 participants perioperatively and 237 participants at 6 months).
MAP= Mean Arterial Pressure. Combined Trial Outcomes included the following complications at 6 months: cardiac morbidity (myocardial infarction, pulmonary edema, adult respiratory distress syndrome and cardiogenic shock); neurologic morbidity (major focal deficit); all-cause mortality; functional decline (>5 point decline in physical component summary measure of the SF-36); and neurocognitive deterioration (within-patient differences on an 11 test neurocognitive battery).

ISSN: 1471-2288